Many pharma companies chase advanced AI without solving the foundational challenge of data integration. With only 10% of firms having unified data, true personalization is impossible until a central data platform is established to break down the typical 100+ data silos.

The primary obstacle to leveraging AI in bioprocessing isn't developing advanced models, but solving the pre-existing, complex challenge of data readiness. Companies are still struggling to unify disparate data from different tools, sites, and GMP vs. development environments, turning intended "data lakes" into inaccessible "data swamps."

The effectiveness of AI agents is fundamentally limited by their data inputs. In the agent era, access to clean and structured web data is no longer a commodity but a critical piece of infrastructure, making tools that provide it immensely valuable. AI models have brains but are blind without this data.

The vast majority of enterprise information, previously trapped in formats like PDFs and documents, was largely unusable. AI, through techniques like RAG and automated structure extraction, is unlocking this data for the first time, making it queryable and enabling new large-scale analysis.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

Companies invest heavily in data but struggle to extract actionable insights. Different business units use disparate data sets, leading to conflicting signals and preventing cohesive, enterprise-wide commercial strategies. The goal is to find the "signal" in the "noise."

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

The primary obstacle to analyzing engineering output was the technical difficulty of synthesizing massive, unstructured data from disparate sources like code repositories, documents, and Slack. It wasn't a cultural issue or lack of tools; it was a data fragmentation problem that AI can now solve.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.